| MONDAY, OCTOBER 27 |
REGISTRATION8:00 a.m.-7:00 p.m.
Research Studies Center, outside of the Hohn Lecture Hall |
EDUCATIONAL SESSIONS10:00 a.m.-12:00 p.m.
- IMPACT OF TRANSLATIONAL RESEARCH ON THE CLINIC – MOLECULAR TARGETED THERAPY AND PATIENT OUTCOME
Chairperson: Clara D. Bloomfield, Ohio State University Comprehensive Cancer Center, Columbus, OH
Clinical Use of Molecular Markers in Curing Acute Myeloid Leukemia
Clara D. Bloomfield
Integration of Molecular Mechanisms of Drug Action into Clinical Treatment Decisions
Gerold Bepler, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Title to be announced
Ravindra Pandey, Roswell Park Cancer Institute, Buffalo, NY
- APPLICATION OF INNOVATIVE TECHNOLOGIES OF THE 21ST CENTURY – AN OVERVIEW
Chairperson: Norma J. Nowak, Roswell Park Cancer Institute, Buffalo, NY
Dynamic Molecular Imaging of Signal Transduction Pathways in Discovery Research
David Piwnica-Worms, Washington University School of Medicine, St. Louis, MO
Biomedical Informatics: Enabling Cancer Researchers to see the Forest AND the Trees
Kenneth H. Buetow, National Cancer Institute, Bethesda, MD
Sequencing the Cancer Genome
Richard K. Wilson, Washington University School of Medicine, St. Louis, MO
|
OPENING LUNCHEON / KEYNOTE TALK
Chairpersons: Raymond N. DuBois, UT M. D. Anderson Cancer Center, Houston, TX and Donald L. Trump, Roswell Park Cancer Institute, Buffalo, NY
12:00 p.m.–1:30 p.m.
Transforming FDA Science: Implications for Cancer Research
Frank M. Torti, Food and Drug Administration, Rockville, MD
|
PLENARY SESSION 1
EXPERIMENTAL AND MOLECULAR THERAPEUTIC ADVANCES – WHAT THE FUTURE HOLDS
Chairperson: Candace S. Johnson, Roswell Park Cancer Institute, Buffalo, NY
1:45 p.m.–3:45 p.m.
Epigenetic Silencing of Endothelial Cells in the Tumor Microenvironment
Candace S. Johnson
Normalizing Tumor Microenvironment to Treat Cancer: From Bench to Bedside and Back
Rakesh K. Jain, Massachusetts General Hospital, Boston, MA
Epigenetic Contributions to Chronic Lymphocytic Leukemia
Christoph Plass, German Cancer Research Center, Heidelberg, Germany
The HIF/VHL Pathway as a Paradigm for the Targeting of the Tumor Microenvironment Therapeutically
Amato J. Giaccia, Stanford University School of Medicine, Stanford, CA
|
PLENARY SESSION 2
THE EMERGING FIELDS OF PROTEOMICS AND SYSTEMS BIOLOGY
Chairperson: Kenneth H. Buetow, National Cancer Institute, Bethesda, MD
4:00 p.m.–6:00 p.m.
Systems Biology and Systems Medicine
Leroy E. Hood, The Institute for Systems Biology, Seattle, WA
Fast Tracking the Development of Cancer Biomarkers Using Proteomics
Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA
Linking Measurement and Mathematics in a Quantitative Analysis of Anti-Cancer Therapy
Peter Sorger, Harvard Medical School, Boston, MA
|
OPENING DINNER / KEYNOTE TALK
7:00 p.m.–9:00 p.m.
Future Trends in Cancer Research
Donald S. Coffey, Johns Hopkins University School of Medicine, Baltimore, MD
|